Newsarchive_old
Overview all archived newsitems
- 12 april: Life Sciences Café
- Brochure: Amsterdam Knowledge Capital verschenen
- Onlangs is de brochure 'Amsterdam Knowledge Capital, where life sciences and business meet' verschenen. De brochure kunt u hier downloaden, een hard copy kunt u opvragen via mz@aimsterdam.nl
- AMT Presents Positive Results of Phase I/II Study
- Amsterdam, The Netherlands - May 31, 2007 - Amsterdam Molecular Therapeutics (AMT), a leader in the field of human gene therapy, reported positive Phase I/II clinical trial results with its lead product AMT-010 (now referred to as AMT-011) in Complete Lipoprotein Lipase (LPL) deficient patients at the 10th Annual Meeting of the American Society of Gene Therapy (ASGT) in Seattle. The study's lead investigator is Erik S.G. Stroes, MD, PhD, from the University of Amsterdam Medical Center in The Netherlands.
- AMT announces pricing of Initial Public Offering on Euronext Amsterdam
- Amsterdam Molecular Therapeutics (AMT) Holding B.V. (to be converted today into a public company with limited liability, Amsterdam Molecular Therapeutics (AMT) Holding N.V.) ("AMT"), a Dutch company active in the field of human gene therapy, announces today that it shall issue 5,000,000 new ordinary shares with a nominal value of €0.04 each (the "Offer Shares") for an offer price of €10.00 (the "Final Offer Price") per share (the "Offering"), subject to the satisfaction of certain conditions on the settlement date of the Offering (which is expected to be on 25 June 2007).
- Clinquest takes stake in Enceladus
- Enceladus Pharmaceuticals and Clinquest Group, both based in Amsterdam, the Netherlands, today announce the signing of an investment and collaboration agreement. Under the terms of the agreement, Clinquest acquires a stake in Enceladus and has led a syndicate of investors to provide additional funding. Financial details are not disclosed. Enceladus will use the new funds for the ongoing clinical development of its proprietary anti-inflammatory drug Nanocort® as a treatment for active Rheumatoid Arthritis.
- Centre and Investment Fund for Life Sciences in Amsterdam
- A number of Amsterdam knowledge centres, three banks, the province of North Holland and the Amsterdam City Council have signed an ‘intervention agreement’ to fund a new Life Sciences Centre and Life Sciences Fund in Amsterdam. ‘This is what Amsterdam Topstad is about,’ said city councilor Lodewijk Asscher. ‘By joining forces, we will be able to make the city stronger and more attractive.’
- ESMO recognizes the NKI for outstanding achievement in translational research in breast cancer
- The European Society for Medical Oncology (ESMO) is pleased to announce that the Netherlands Cancer Institute (NKI) is the winner of the second edition of the ESMO Lifetime Achievement Award supported by an unrestricted grant from GlaxoSmithKline (GSK).
- Avantium announces development activities for novel biofuels
- During the visit of the Deputy Mayor of Amsterdam, Mr. Lodewijk Asscher, Avantium has announced that it is active in developing a novel generation of biofuels.
- Skyline Diagnostics wint BioBusiness Start-up of the Year Award 2007
- Skyline Diagnostics heeft de BioBusiness Start-up of the Year Award 2007 gewonnen. De prijs werd tijdens het BioBusiness Event op 31 mei overhandigd door Joke van Antwerpen, directeur van de Amsterdam Innovation Motor. Aan de prijs is een geldbedrag van tienduizend euro verbonden.
- Agendia BV raises €25 Million ($34M) and Receives Second FDA Clearance
- Agendia BV., world leader in the rapidly evolving field of molecular diagnostics, announced today that it has raised €25 million ($34 M) in a fourth financing round. ING, one of the largest bank-insurers, becomes a shareholder of Agendia.
- OMS boekt succes in ontwikkeling test blaaskanker
- Biotechnologiebedrijf OncoMethylome Sciences (OMS) heeft succes geboekt bij de ontwikkeling van een test om blaaskanker op te sporen. Dat heeft het bedrijf, dat een notering heeft aan de effectenbeurs in Amsterdam, dinsdag bekendgemaakt.
- Agendia joins the Personalized Medicine Coalition (PMC)
- Agendia BV, a world leader in the rapidly evolving field of cancer molecular diagnostics, announces that it has joint the US-based Personalized Medicine Coalition (PMC).
- The Netherlands Genomics Initiative (NGI) will invest M€ 15 in Systems Biology
- The Dutch government approved the NGI business plan for 2008-2012 with a total budget of M€ 271.
- NGI announces Business Plan 2008 – 2012
- The Netherlands Genomics Initiative is proud to announce the government's approval of its 2008 - 2012 Business Plan, which totals up to EUR 280 million. The budget for valorisation has been drastically increased, which underlines NGI’s commitment to create tangible value from research results.
- NVF Organon Prijs voor Farmacologie voor Prof. Dr. Martine Smit, Vrije Universiteit Amsterdam
- Martine Smit heeft maandag 1 oktober de NVF Organon Prijs voor Farmacologie in ontvangst genomen.
- Thesis defence: prognostic factors head and neck carcinoma
- On November 8, 2007 F. J. P. Hoebers, Universtity of Amsterdam, will defend his PhD thesis describing a number of studies aimed at applying or developing prognostic and predictive tests in order to be able to improve the (future) selection of patients for the appropriate treatment.
- Breast Cancer Research Foundation Award for Laura van 't Veer
- Tuesday October 15th the Pink Ribbon 'Breast Cancer Research Foundation' granted in New York awards to 151 international breast cancer researchers.
- Avantium intends to list on Euronext Amsterdam
- 23 October 2007-Positive results with next generation biofuels trigger IPO plans.
- Revamp Amsterdam BioMed webportal
- As the life sciences sector grows and the Cluster gains momentum, the Amsterdam BioMed portal is redesigned to build an interactive regional life sciences community.
- Opening of the new Business to Science Portal Holland
- A new portal for knowlege questions in the Dutch province Zuid-Holland will open soon. The portal, by the name Business to Science Portal Holland, will facillitate small to mid size companies in the field of Life Sciences and medical technology. The participating knowlege institutions will actively contact companies in the region to asses their needs for specific knowlege.
- Quarter of Dutch university professors financed by external party
- As often the external party is not revealed, this development is potentially harmful when companies circulate company news disguised as scientific findings. VU University Professor Martijn Katan pleas for stronger regulation to counteract conflicts of interest.
- Crucell Announces First in Man Study with New Adenovirus Vector
- The vector was developed by Crucell and the Beth Israel Deaconess Medical Center. In the phase I clinical study the vector will be used to test a new HIV vaccine.
- Biomarkers May Predict Effect of drugs aimed at limiting tumor blood supply
- 13 April 2008-Drugs that cut off the blood supply to tumors, such as Genentech Inc.'s Avastin and Pfizer Inc.'s Sutent, may work better for patients with high numbers of cells in the blood that are thought to form the new lining for vessels. ``You need a biomarker to tell you which patients will benefit,'' said Laura Vroling, a cancer researcher at VU University Medical Center in Amsterdam, in an interview.
- New Life Sciences Center Oostervaart in Lelystad
- The building is an initiative of MAC3PARK Business centers to support Life Science oriented businesses. The interior was financed by the province of Flevoland and the EU fund for regional development. At the moment of writing, seven companies are active at the location.
- 2,3 million grant for Computational Life Sciences
- Two Computational Life Sciences projects of the VU medical center in Amsterdam will be financed from a 2,3 million grant. The grant is an initiative of the NWO-Exacte Wetenschappen, Netherlands Bioinfomatics Centre (NBIC) and the Netherlands Genomics Initiative (NGI) to stimulate research i the Computational Life Sciences. Out of 41 projects submitted, five were selected to be financed.
- Stem cells isolated from adult heart tissue
- Researchers of the University of Utrecht managed to isolate stem cells from adult heart tissue. The researchers managed to let the cells develop into beating heart cells.
- Biotech sector leads in attracting venture capital investment
- The MoneyTree report by PricewaterhouseCoopers and the National Venture Capital Association noted that Biotech attracted more venture capital than any other sector in the first quarter of this year, with about $1.27 billion in funding. The total amount of venture capital investments was 4.8% lower than last year.
- LSP to advise ABP on investments in the Life Sciences sector
- 5 May 2008-The Dutch civil servants pension fund ABP is going to invest in small European biotechnology funds. The private-equity house Life Sciences Partners (LSP) will advise ABP on the selection of companies. With 200 billion Euro, the ABP is one of the largest pension funds in the world.
- Two billion euro boost for medical research in Europe
- 30 April 2008-In order to give medical research in the EU a boost, the European Commission and the pharmaceutical industry will invest €2bn in small businesses and academic researchers. The Innovative Medicines Initiative aims at re-establishing Europe as a leading developer of medicines.
- Amsterdam: Top-business city
- 9 June 2008-For the first time, Amsterdam belongs to the top ten of most important business cities world-wide.
- BCF Event 2008 very successful
- 28 May 2008-The fourth edition of the BCF Event was held in Amsterdam on 21 May.
- BIO 2008: visit us at the Holland Pavilion, booth #3135!
- 10 June 2008-The Amsterdam BioMed Cluster and the Life Sciences Centre Amsterdam will be exhibiting at the 2008 Bio International Convention, June 17-20, in San Diego, USA.
- Dutch Life Sciences popular with foreign talent
- 10 June 2008-The International Talent meets Dutch Life Sciences project was held 19-22 May.
- Microbiome Ltd wins Amsterdam Invention Award 2008
- 25 June 2008-Microbiome Ltd, a spin off of the VU medical centre, developed a test to detect Chlamydia.
- ERC Starting Grants
- 1 July 2008-ERC Starting Independent Researcher Grants (ERC Starting Grants) aim to support up-and-coming research leaders who are about to establish or consolidate a proper research team and to start conducting independent research in Europe. The new call is expected to be published in July 2008, with deadlines after the summer.
- Governer Blunt (state Missouri) met Niaba
- 25 July 2008-Gov. Matt Blunt met Thursday with the Netherlands Biotech Industries Association (Niaba) and officials from Monsanto-Seminis in an effort to grow Missouri's biotechnology sector.
- Odanacatib reduced markers of bone turnover in women with breast cancer and bone metastases
- 30 June 2008-Merck & Co., USA, which operates in the Netherlands as Merck Sharp & Dohme or MSD, announced results of a new study in which its investigational selective cathepsin K inhibitor odanacatib reduced measures of bone turnover (breakdown and rebuilding of bone) in women with breast cancer that has spread to the bones (bone metastases).
- Dutch Cabinet awards NGI € 271 million
- The Netherlands Genomics Initiative (NGI) is pleased to announce the decision of the Dutch cabinet to award NGI a second phase.
- VUmc Radionucliden Centrum: Moleculair maatwerk
- Een PET-scanner kan zeer nauwkeurig biochemische processen in beeld brengen, zoals die bijvoorbeeld plaatsvinden in ontstekingen en tumoren.
- Kiadis intends to list on Euronext
- 2007 Kiadis Pharma, an oncology focused pharmaceutical development company today announces its intention to raise new funds through an IPO
- St. Lucas Andreas Hospital first to start home monitoring of cardiac patients using Philips remote system
- This will not only improve these patients’ quality of life, but could also prevent many hospital admissions.
- Avantium to deliver Flowrence™ systems to Shell
- 2 November 2007-Under the agreement Avantium will sell and deliver Flowrence™ Research platforms to CRI/Criterion or its affiliates to enhance its research capabilities.
- Expat Center for Amsterdam area to open in spring 2008
- With the opening of the Expat Center foreign knowledge workers will have only one desk to turn to arrange their work and living in the Amsterdam area.
- FDA grants Kiadis Pharma lead product ATIR orphan drug designation
- Kiadis Pharma announced today that its lead product ATIR has been granted orphan drug designation by the US Food and Drug Administration (FDA).
- The University of Amsterdam ranks highest of Dutch Universities in THES-QS World University Rankings 2007
- According to Martin Ince, of the Times Higher Education Supplement “The 2007 THES-QS World University Rankings are the most rigorous and complete so far. They show that the US and UK model of independent universities supported with significant state funding produces great results, but they also prove that academic excellence is found on every continent.”
- New anti cancer medication heightens effect of radiation treatment
- 2 November 2007-Radiation treatment in combination with administering of the substance perifosine appears to have a strong tumor neutralizing impact in test animals.
- Businesses welcome critical professor
- The director of the Centre for Diabetes and professor diabetology leaves Amsterdam for Indianapolis and starts as executive medical director at the pharmaceutical concern Lilly at the start of the new year.
- Reduced functioning of smaller blood vessels could have great consequences
- The fact that risk factors for cardiovascular diseases, like high blood pressure and insulin sensitivity, appear in combination is possibly due to a reduced functioning of the smaller blood vessels.
- Crucell Announces Marketing and Distribution Deal with Sanquin
- 12 november 2007-Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL, Swiss Exchange: CRX) today announced the start of a marketing and distribution agreement with Sanquin, the Dutch Blood Supply Foundation.
- Sanquin-studie haalt Science: 'Vreemdgaan in de bloedbaan'
- 12 September 2007-Lang niet alle antistoffen zijn zo stabiel als werd gedacht. Sommige van de Y-vormige eiwitten kunnen in onze bloedbaan fragmenten met elkaar uitwisselen, waardoor één antistof aan twee verschillende indringers kan binden. In het wetenschappelijke tijdschrift Science beschrijven immunologen van Sanquin deze week samen met onderzoekers van de Universiteit Maastricht en het Utrechtse bedrijf Genmab als eersten een verklaring voor deze bijzondere uitwisseling. Hun vondst heeft positieve consequenties voor nieuwe therapieën tegen auto-immuunziekten.
- Due to adverse market conditions Avantium withdraws its intitial public offering
- Avantium, a leading technology company in the area of advanced high-throughput R&D, withdraws its Initial Public Offering (“IPO”) planned for 16 November 2007 due to adverse markets. Avantium will continue implementing its communicated strategy and closely monitor the development of the capital markets.
- In biology, polarization is a good thing
- Using a molecular cellular compass, individual cells in complex organisms know which way is up or down, in epithelial cells known as apical-basal polarity. Determining the orientation is essential for an individual cell to perform it’s designated tasks. Now it appears that the same compass also defines the direction of cells when migrating by establishing a morphological back and a front. These are the conclusions of a recent study lead by drs Michiel Pegtel and John Collard from the Netherlands Cancer Institute.
- Crucell's Rabies Antibody Cocktail Granted Fast Track Status
- Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL, Swiss Exchange: CRX) today announced that it has been notified by the Food and Drug Administration's (FDA) Department of Health and Human Services that its rabies monoclonal antibody cocktail has been granted a Fast Track designation.
- A novel family of antibiotics against tuberculosis and salmonella target pathways active in cancer
- 29 november 2007-Researchers have discovered new ways to fight bacterial infections including extensively drug-resistant tuberculosis. The work will be published in the journal Nature on 29 November.
- Life saving plasma product by Sanquin now also available internationally
- 4 December 2007-Preventie van trombose vindt plaats via antistollingsmiddelen. Soms is het nodig om die antistolling direct te corrigeren zoals in geval van ernstig trauma, urgente chirurgie of levensbedreigende bloedingen. Direct herstel van de stolling vindt plaats met Cofact. Sanquin heeft een overeenkomst afgesloten met biotechnologiebedrijf Crucell voor de buitenlandse distributie.
- Sanquin besteedt groot deel ICT-ondersteuning uit aan EDS
- 4 December 2007-Sanquin, de stichting die in Nederland verantwoordelijk is voor de bloedvoorziening en onderzoek en ontwikkeling van bloedproducten, heeft een nieuw meerjarig contract afgesloten met EDS.
- 3rd Life Sciences Capitals congress great success!
- At the succesful investors forum 10 companies presented a business case. Ada Kruisbeek, Co-founder of the Amsterdam BioMed Cluster, received 40 hours of professional consultancy for the best pitch of her company DCPrime BV.
- Letter of intent signed for launch “Spinoza centre” in Amsterdam
- The Royal Dutch Academy of Arts and Sciences has taken the initiative to bundle activities and facilities in the field of neuroimaging in order to build an internationally renowned institute. The VU University/ VU University Medical Centre, the University of Amsterdam, and the Academic Medical Centre participate in the “Spinoza centre”.
- BMEYE™ announces FDA 510(K) Clearance for Nexfin™
- Now also cardiologists and clinicians in the USA, who need to measure continuous non-invasive blood pressure and cardiac output, can benefit from BMEYE’s newly developed line of safe, precise and easy to use hemodynamic monitors.
- Science article describes direct observation of chaperone-induced changes in a protein folding pathway
- Insight in the folding of proteins may help to understand diseases that occur due to proteins (un)folding incorrectly like in Alzheimer’s, report scientists from Groningen and Amsterdam
- Petrobras and Avantium announce research collaboration
- Petrobras and Avantium will collaborate on the development of new catalysts for emerging technologies within Petrobras, Brazil’s largest energy company.
- ATIR classified as “cell based” medicinal product by the EMEA; a classification for innovative new treatments
- As a next step Kiadis Pharma will file for orphan drug designation with the EMEA as already granted by the US Food and Drug Administration last November.
- New lab for visualization and analyses of large numbers of data
- The 13th of December the first Dutch e-BioScience Laboratory (e-BioLab for short) was opened on the site of Science Park Amsterdam.
- OncoMethylome Sciences to Collaborate with GlaxoSmithKline Biologicals for Personalized Cancer Treatment
- The goal of the collaboration is to develop DNA methylation biomarkers for use in the personalization of cancer treatment with certain immunotherapeutics in development by GSK Biologicals.
- OncoMethylome's Biomarkers Demonstrate Good Performance in Detecting Colorectal Cancer in Blood
- The goal of OncoMethylome's colorectal cancer program is to develop accurate, non-invasive, and user-friendly tests that are appropriate for population screening. Colorectal cancer is the second leading cause of cancer-related death in the US and Europe.
- A novel family of antibiotics against tuberculosis and salmonella target pathways active in cancer
- Researchers have discovered new ways to fight bacterial infections including extensively drug-resistant tuberculosis. The Dutch work is published in the journal Nature.
- Kiadis Pharma reports successful End of Phase II Meeting with FDA for Reviroc
- 19 December 2007-Reviroc is under development for elimination of cancer cells from an autologous graft in bone marrow transplantations for end-stage blood cancer patients. The FDA offered its Special Protocol Assesment procedure for Reviroc.
- NKI scientist Sophia Bruggeman wins Antonie van Leeuwenhoek award
- The Antonie van Leeuwenhoek prize was awarded to Sophia Bruggeman for her research on the role of the polycomb-protein Bmi-1 in the development of brain tumors by an alternative route.
- Cancer clinic canceled
- 19 January 2008-It would have been the first commercial cancer institute in the Netherlands, but after failure of investor Rehamed to comply to payment obligations the city of Amsterdam pulled the plug.
- Discovery of several hundreds of potential cancer genes
- 15 May 2008-Researchers have found over 250 new genes that are potentially involved in the development of leukemia (cancer of white blood cells).
- Breakthrough in malaria testing
- 21 May 2008-Researchers of the Royal Tropical Institute (KIT) in Amsterdam and English scientists have developed a quick and cheap test to detect malaria.
- BioBusiness Award 2008 for IsoBionics
- 23 May 2008-IsoBionics received the BioBusiness Award 2008, the award for the most promising start-up in Life Sciences and biomedical technology in 2007.
- Prof. dr. Dick Swaab received the Academiepenning 2008
- 19 May 2008-Prof. dr. Dick Swaab (UvA/AMC, Amsterdam) was awarded the Academiepenning 2008 by the Royal Netherlands Academy of Arts and Sciences (KNAW).
- Two Dutch young patients killed by resistant influenza virus H1N1
- 23 May 2008-In Utrecht and Rotterdam, a patient was killed due to influenza virus H1N1, that became resistant to Tamiflu. In the Netherlands, 6 percent of the monitored H1N1 viruses are resistant.
- Bone repair using patient's own stem cells
- 26 May 2008-Researchers at the University of Twente have shown that substantial bone can be formed when the enzyme PKA is previously activated in the stem cells before implantation.
- NWO-Spinozapremie 2008 for prof. dr. Marjo van der Knaap
- 2 June 2008-Prof. dr. Marjo van der Knaap (VUmc, Amsterdam) received the NWO-Spinozapremie 2008 for her research on serious brain abnormalities in children.
- KP7 for innovation in Health and Life Sciences opens July 24th 2008
- 9 June 2008-The 7th framework program for R&D in Health and Life Sciences (KP7) is a grant offered by the European Commission. Health/Life Sciences are one of the priorities of the KP7.
- OncoMethylome's Novel Test for Bladder Cancer Demonstrates Excellent Performance in Clinical Trial
- 28 May 2008-OncoMethylome Sciences (Euronext Brussels: ONCOB, Euronext Amsterdam: ONCOA) released additional data from an ongoing clinical verification trial of their bladder cancer test.
- Report defends drug companies
- 24 June 2008-Critics accuse drug companies of reaping obscene financial reward for little that is innovative.
- Agendia expands laboratory capacity at new headquarters
- 23 June 2008-Agendia BV has announced the official opening of the company's new headquarters at Amsterdam's Science Park.
- Genzyme and Isis complete licensing of mipomersen
- 24 June 2008-Genzyme Corp. and Isis Pharmaceuticals announced the finalisation of the license and collaboration agreement for mipomersen.
- Life sciences network expands east of Scotland
- 4 August 2008-Life science companies in the east of Scotland are to get their own network to support local businesses and academic research.
- Major health research group (UCL Partners) operational from September
- 7 August 2008-Five London medical centres (University College London (UCL), Great Ormond Street Hospital, Moorfields Eye Hospital, Royal Free Hampstead and UCL Hospitals) have joined forces to become Europe's largest academic health science partnership.
- Genetic basis of “Volendam disease” unravelled
- 18 August 2008-Scientists of the Amsterdam Medical Center and the University of Keulen found new gene mutations that are correlated with the rare, serious brain disorder pontocerebellair hypoplasy, which is known as the “Volendam disease”. The discovery allows an earlier diagnose of the disorder.
- Call for project proposals in Computational Life Sciences
- 7 September 2008-The program Computational Life Sciences (CLS) will result in new insights in biological networks. In total, about 2.5 million euro will be divided by the financers NWO-Exact Sciences, Netherlands Bioinfomatics Centre (NBIC) and the Netherlands Genomics Initiative (NGI). The deadline is October 15 2008 12 o’clock.
- Cancer survival varies widely between countries
- 20 August 2008-A worldwide population-based study provides survival estimates for 1.9 million adults diagnosed with a first, primary, invasive cancer of the breast (women), colon, rectum, or prostate by use of individual tumour records from 101 population-based cancer registries in 31 countries on five continents.
- Western European diabetes market shows movement to exclusive pill therapy
- 2 September 2008-For diabetes patients across the Western European countries of France, Germany, Italy, the Netherlands, Spain and the United Kingdom, exclusive pill therapy is increasingly the treatment of choice.
- EMEA grants Kiadis Pharma lead product ATIR™ orphan drug designation
- 22 September 2008-Kiadis Pharma announced today that its lead product ATIR™ has been granted orphan drug designation (ODD) by the European Medicines Agency (EMEA) for the prevention of acute Graft versus Host Disease (GvHD) following an allogeneic bone marrow transplantation.
- TYSABRI® demonstrates sustained improvement in functional outcomes in Multiple Sclerosis patients
- 19 September 2008-Biogen Idec and Elan Corporation, plc announced that a post-hoc analysis showed TYSABRI® (natalizumab) treatment increases the probability of achieving sustained improvement in physical disability over two years when compared to placebo.
- Report: the era of Old IP is starting to wane and needs to be replaced
- 9 September 2008-The International Expert Group on Biotechnology, Innovation and Intellectual Property recognised a critical need to direct the change from Old Intellectual Property to New IP (i.e. focusing on granting the right amount of IP and better use of it) in order to ensure the appropriate development, production and distribution of medicines, foods and industrial processes (such as the production of clean fuels).
- Inflatable pill delivers medicine to the tumor
- 30 September 2008-Philips developed a new method to deliver medicine on the location wanted in the body using sound.
- New brain cancer research consortium funded by Ivy Foundation aims to improve personalised medicine for patients
- 8 July 2008-The Ivy Genomics-Based Medicine Project (Ivy G.B.M. Project) is a collaboration among nine U.S. institutions working together to try to better understand how the genetic differences in individual brain tumours can potentially inform the prediction of what will be the most effective treatment option for each patient.
- Bruker Daltonics Showcased Novel Proteomics Solutions Based on Mass Spectrometry
- 17 August 2008-Bruker Daltonics showcased several new high performance mass spectrometry products and applications for proteomics at the 7th HUPO World Congress 2008.
- Solvay Pharmaceuticals acquires Innogenetics
- 9 September 2008-Solvay Pharmaceuticals S.A. succeeded to acquire Innogenetics N.V., a Belgian-based biotechnological company.
- Innovation within Dutch Life Sciences & Medical Technology must pick up momentum
- 18 August 2008-Innovation in the Dutch Life Sciences & Medical Technology sector is lagging behind due to a gap between knowledge development and knowledge application.
- Nobel Prize in Medicine 2008 awards discoveries of two viruses causing severe human diseases
- 6 October 2008-The Nobel Assembly at Karolinska Institutet has today decided to award The Nobel Prize in Medicine for 2008 with one half to Harald zur Hausen for his discovery of "human papilloma viruses causing cervical cancer" and the other half jointly to Françoise Barré-Sinoussi and Luc Montagnier for their discovery of "human immunodeficiency virus".
- BioBusiness summer school proves a success
- 3 October 2008-The first edition of the BioBusiness summer school this year in Amsterdam has been a great success according to the participants’ evaluation report.
- The Ig® Nobel Prizes
- 2 October 2008-The 2008 Ig Nobel Prizes were awarded on Thursday October 2 at the 18th Annual Ig Nobel Prize Ceremony at Harvard’s Sanders Theatre.
- European phase III study on diabetes vaccine
- 1 October 2008-The Swedish biopharmaceutical company Diamyd Medical is focusing on development of pharmaceuticals for treatment of autoimmune diabetes and its complications.
- City of Amsterdam awarded prof. H. M. Pinedo
- 31 October 2008-The City of Amsterdam awarded the silver medal to prof. H. M. Pinedo. He received the medal during his farewell symposium in the ING House.
